H.C. Wainwright Keeps Their Buy Rating on Denali Therapeutics (DNLI)

Tip Ranks
2025.12.04 07:55
portai
I'm PortAI, I can summarize articles.

H.C. Wainwright analyst Andrew Fein maintains a Buy rating on Denali Therapeutics, setting a price target of $32.00. Shares closed at $19.00, with a consensus price target of $31.00, indicating a 63.16% upside. B. Riley Securities also maintains a Buy rating with a $30.00 target. Fein has a 26.5% average return and a 54.36% success rate on stocks.

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $32.00. The company’s shares closed yesterday at $19.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Fein covers the Healthcare sector, focusing on stocks such as Alector, Prothena, and Palvella Therapeutics. According to TipRanks, Fein has an average return of 26.5% and a 54.36% success rate on recommended stocks.

Denali Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $31.00, implying a 63.16% upside from current levels. In a report released on December 1, B. Riley Securities also maintained a Buy rating on the stock with a $30.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer